Silence Therapeutics Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Silence Therapeutics stock has a consensus rating of "Buy" and an average price target of $29.17. The average 1-year stock price forecast is 187.67% higher than the current stock price, while the lowest is $4.00 (-60.55%) and the highest is $75 (+639.64%).

Price Target: $29.17 (+187.67%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$4.00	$29.17	$25	$75
Change	-60.55%	+187.67%	+146.55%	+639.64%

Analyst Ratings

The average analyst rating for Silence Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Jan '26	Feb '26	Mar '26	May '26	Jun '26
Strong Buy	4	4	4	4	4	5
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	1	1
Total	6	6	6	6	6	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Prakhar Agrawal Cantor Fitzgerald	Cantor Fitzgerald	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Jun 24, 2026
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $75	Buy	Reiterates	$75	+639.64%	Jun 17, 2026
Michael Ulz Morgan Stanley	Morgan Stanley	Buy Reiterates $25	Buy	Reiterates	$25	+146.55%	Jun 12, 2026
Myles Minter William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Jun 11, 2026
Keay Nakae Chardan Capital	Chardan Capital	Buy Maintains $35 → $27	Buy	Maintains	$35 → $27	+166.27%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.34M

from 559.00K

497.02%

from 559.00K

Revenue Next Year

4.60M

from 3.34M

37.76%

from 3.34M

EPS This Year

-0.37

from -

EPS Next Year

4.79

from -0.37

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	16.81M	21.66M	31.64M	43.26M	559.00K	3.34M
Revenue Growth	124.73%	28.82%	46.12%	36.71%	-98.71%	497.02%
Gross Profit	6.71M	8.19M	18.78M	31.45M	344.00K	3.33M
Gross Margin	39.94%	37.83%	59.34%	72.70%	61.54%	99.80%
Operating Income	-62.03M	-51.22M	-52.43M	-49.58M	-82.29M	-67.84M
Net Income	-53.36M	-50.33M	-54.23M	-45.31M	-88.61M	-67.29M
EPS	-	-	-	-	-	-0.37
Free Cash Flow	-6.72M	-26.84M	-23.31M	-25.37M	-39.55M	-75.67M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	18.3M
Avg	3.3M
Low	414,232

Revenue Growth

Revenue Growth	2026	2027	2028
High	3,177.2%
Avg	497.0%
Low	-25.9%

EPS Forecast

EPS	2026	2027	2028
High	-0.37
Avg	-0.37
Low	-0.37

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-